Your browser doesn't support javascript.
loading
Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade.
Jagodinsky, Justin C; Vera, Jessica M; Jin, Won Jong; Shea, Amanda G; Clark, Paul A; Sriramaneni, Raghava N; Havighurst, Thomas C; Chakravarthy, Ishan; Allawi, Raad H; Kim, KyungMann; Harari, Paul M; Sondel, Paul M; Newton, Michael A; Crittenden, Marka R; Gough, Michael J; Miller, Jessica R; Ong, Irene M; Morris, Zachary S.
Afiliação
  • Jagodinsky JC; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Vera JM; Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
  • Jin WJ; Department of Statistics and Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA.
  • Shea AG; Sage Bionetworks, 2901 Third Ave. Suite 330, Seattle, WA 98121, USA.
  • Clark PA; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Sriramaneni RN; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Havighurst TC; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Chakravarthy I; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Allawi RH; Department of Statistics and Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA.
  • Kim K; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Harari PM; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Sondel PM; Department of Statistics and Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA.
  • Newton MA; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Crittenden MR; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Gough MJ; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
  • Miller JR; Department of Statistics and Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA.
  • Ong IM; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, NE Glisan St., Portland, OR 97213, USA.
  • Morris ZS; Oregon Clinic, Portland, OR 97232, USA.
Sci Transl Med ; 16(765): eadk0642, 2024 Sep 18.
Article em En | MEDLINE | ID: mdl-39292804
ABSTRACT
Radiation therapy (RT) activates multiple immunologic effects in the tumor microenvironment (TME), with diverse dose-response relationships observed. We hypothesized that, in contrast with homogeneous RT, a heterogeneous RT dose would simultaneously optimize activation of multiple immunogenic effects in a single TME, resulting in a more effective antitumor immune response. Using high-dose-rate brachytherapy, we treated mice bearing syngeneic tumors with a single fraction of heterogeneous RT at a dose ranging from 2 to 30 gray. When combined with dual immune checkpoint inhibition in murine models, heterogeneous RT generated more potent antitumor responses in distant, nonirradiated tumors compared with any homogeneous dose. The antitumor effect after heterogeneous RT required CD4 and CD8 T cells and low-dose RT to a portion of the tumor. At the 3-day post-RT time point, dose heterogeneity imprinted the targeted TME with spatial differences in immune-related gene expression, antigen presentation, and susceptibility of tumor cells to immune-mediated destruction. At a later 10-day post-RT time point, high-, moderate-, or low-RT-dose regions demonstrated distinct infiltrating immune cell populations. This was associated with an increase in the expression of effector-associated cytokines in circulating CD8 T cells. Consistent with enhanced adaptive immune priming, heterogeneous RT promoted clonal expansion of effector CD8 T cells. These findings illuminate the breadth of dose-dependent effects of RT on the TME and the capacity of heterogeneous RT to promote antitumor immunity when combined with immune checkpoint inhibitors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Microambiente Tumoral / Inibidores de Checkpoint Imunológico Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Microambiente Tumoral / Inibidores de Checkpoint Imunológico Idioma: En Ano de publicação: 2024 Tipo de documento: Article